ABAna Peláez Bejarano

Ana Peláez Bejarano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Peláez Bejarano has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • L Gomez-Sayago

    Hospital General De Riotinto, Farmacia Hospitalaria, Huelva, Spain

    2 shared publications
  • A Inoriza Rueda

    Unidad de Gestión Clínica Oncología Médica, Hospital Juan Ramón Jiménez, Huelva, Spain

    1 shared publication
  • A. Jiménez-Hidalgo

    Unidad de Gestión Clínica Enfermedades Infecciosas, Hospital Juan Ramon Jimenez, Huelva, Spain

    1 shared publication
  • Ana Belén Guisado-Gil

    Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Seville, Spain

    1 shared publication
  • E Rodrigues Molins

    Hospital General De Riotinto, Farmacia Hospitalaria, Huelva, Spain

    1 shared publication
  • Ernesto Sánchez Gómez

    Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva 21005, Spain

    1 shared publication

Latest Publications

  • Open Access

    4CPS-035 Association of dihydropyrimidine dehydrogenase deficiency with capecitabine tolerance

    by A Peláez Bejarano, E Rodrigues Molins, L Gomez-Sayago

    Background and Importance Dihydropyrimidine dehydrogenase (DPD) is the first of the enzymes in the fluoropyrimidine metabolic pathway. Recently, the Spanish Agency of Medicine and Health Products reported an informative note warning that patients with partial or total deficiency in DPD activity cannot adequately degrade fluoropyrimidines, increasing the risk of serious toxicity. DPD genotyping is recommended as standard practice for predicting the occurrence and severity of capecitabine toxicity. Aim and Objectives To assess the rate of deficiency of the metabolising enzyme DPD in patients treated with capecitabine and to describe the associated toxicity. Material and Methods A retrospective observational study was conducted during 2022 in a regional hospital. Age, gender, Eastern Cooperative Oncology Group (ECOG) and diagnosis were collected from the electronic clinical history. To determine the variants of DPD, a pharmacogenomics analysis was performed using a real-time polymerase chain reaction technique. The polymorphisms studied were rs3918290, rs55886062, rs67376798 and rs56038477. Regarding the management of patients, the doses reduction, adverse events (AE), and withdrawal treatments were recorded. Results Thirty-six patients were included with median age 70.9 (50–88) years. ECOG 0–1 was observed in 94% of cases. Capecitabine was used for the following diagnoses: colorectal cancer (n=22, 61%), gastric cancer (n=9, 25%) and breast cancer (n=5, 14%). DPD genotyping was performed on 25 patients (69%). A mutated allele heterozygote was detected in 3 (8.3%) patients: rs56038477 (n=2, 5.5%) and rs67376798 (n=1, 2.8%). A 50% dose reduction was prescribed initially according to pharmacogenetics recommendations in DPD deficiency and this dose was maintained throughout the entire treatment. In patients without mutation a dose reduction was required in 8 (32%). All patients with DPD mutation and 20 (80%) without DPD mutation presented AE. The most common AE in this population were weakness (n=18, 50%), diarrhoea (n=17, 47.2%), gastrointestinal such as nausea (n=10, 27.8%), dactylitis (n=8, 22.2%), mucositis (n=8, 22.2%), paraesthesia (n=8, 22.2%),hyperpigmentation (n=6, 16.7%) and constipation (n=4,11.1%). Six (16.7%) discontinuations of capecitabine due to AE were reported. Conclusion and Relevance It is important to know the DPD polymorphism to correctly adjust the capecitabine dose. A considerable percentage of patients without DPD mutation report AE. Determination of variants of DPD can help avoid serious or fatal EA. Conflict of Interest No conflict of interest

  • Open Access

    4CPS-036 Successful treatment of post-surgical meningitis caused by bacillus cereus: a case report

    by A Peláez Bejarano, Jm Garcia De Lomas, Fj Martinez Marcos, L Gomez-Sayago

    Background and Importance Bacillus cereus is a spore-forming, gram-positive bacterium that is ubiquitous in the environment. It is frequently dismissed as contaminants, however, in the proper setting these organisms have the potential to be virulent. Clinical infections caused by B. cereus fall into six broad groups: local infections of wounds, burns, bacteraemia, CNS infections, respiratory infections, endocarditis and food poisoning. Despite aggressive treatment with broad-spectrum antibiotics and using them appropriately, the mortality is high. Aim and Objectives To describe a case of Bacillus cereus central nervous system infection associated with post-surgical meningitis and a patient successfully treated with antibiotics. Material and Methods Descriptive and retrospective clinical case. Data were obtained by review of electronic medical records. Results A 72-year-old woman underwent a decompressive laminectomy due to lumbar spinal stenosis. Past medical history included hypertension and dyslipidaemia. She was discharged without complications. One week later, the patient was brought to the emergency room for altered consciousness, dysarthria, hemiplegia and fever. Her vital signs included a blood pressure of 109/82 mmHg, heart rate 125 beats/min, SpO2 92%, and Glasgow Coma Scale score of 7/15. C-reactive protein (CRP) level was 95 mg/l (reference Bacillus cereus was isolated. The isolate was found resistant to β-lactam antibiotics (including penicillin, ampicillin and cephalosporin) and trimethoprim/sulfamethoxazole, and showed susceptibility to macrolides, vancomycin, clindamycin, carbapenems and quinolones. Triple antibiotherapy with meropenem, vancomycin and linezolid was initiated. After a few days of clinical stability, absence of fever and negative microbiological cultures, the triple antibiotic therapy was withdrawn and vancomycin and meropenem were continued. With adequate control of the source of infection and after a good evolution of the surgical wound, antibiotic therapy was switched to the oral route with linezolid. The patient was discharged with no evidence of sequelae from the meningeal infection, normal neurologic examination and CRP levels within the normal range. Conclusion and Relevance This case highlights the clinical challenge to diagnose B. cereus and the importance of the delay between the detection of B. cereus and the establishment of an effective, targeted antibiotic therapy, especially in immunocompromised patients. Conflict of Interest No conflict of interest

  • Successful treatment of postsurgical meningitis caused by Bacillus cereus : a case report and literature review

    by A. Peláez Bejarano, J. M. García de Lomas, M. Franco-Huertas, F. J. Martínez-Marcos, A. Jiménez-Hidalgo

    Bacillus cereus is a spore-forming, gram-positive bacterium that is ubiquitous in the environment. Central nervous system involvement with B. cereus is rare. Despite aggressive treatment with broad-spectrum antibiotics and using them appropriately, the mortality is high. A 72-year-old patient suffered a central nervous system infection associated with postsurgical meningitis and was successfully treated with a novel antibiotic therapy. This study includes the first case report of postsurgical B. cereus meningitis in the last ten years. It provides a different line of treatment to the previous ones.


  • Successful treatment of Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime/avibactam and aztreonam

    by Ana Pelaez Bejarano, Raquel Sánchez-Del Moral, Olalla Montero-Pérez, Francisco Javier Martínez-Marcos

    The case of a female who had an accident that caused an open fracture is reported. During hospitalisation, Verona integron-encoded metallo-β-lactamase (VIM)-producing Klebsiella pneumoniae was isolated. Antimicrobial susceptibility testing revealed resistance to β-lactam antibiotics, quinolones, trimethoprim/sulfamethoxazole, and susceptibility to tigecycline, colistin, fosfomycin and aminoglycosides. Synergistic activity of ceftazidime-avibactam and aztreonam was proved in vitro and a combined therapy with tigecycline was started. Combination with aminoglycosides was ruled out as it was not described in the literature and also in order to avoid side effects. Colistin was rejected because of its nephrotoxicity profile. The antibiotic treatment was assessed by a multidisciplinary team with a pharmacist who closely monitored adverse effects and interactions with other drugs. The total duration of this combination was 25 days, without any adverse events reported. Fourteen weeks after the accident the patient was discharged. After 2 months of follow-up neither relapses nor reinfections have been reported.


  • Patient experience in a rare disease: application of the IEXPAC questionnaire in hereditary transthyretin-mediated amyloidosis

    by Ana Peláez Bejarano, Maria de Las Aguas Robustillo Cortés, Maria Isabel Guzman Ramos

    Background: Hereditary transthyretin amyloidosis (hATTR amyloidosis) is a rare, disabling and potentially fatal disease. The purpose of this investigation was to analyze the experience reported by hATTR amyloidosis population and develop a strategy to improve results for patients searching Internet for knowledge about their disease. Methods: A cross-sectional study, including adult hATTR amyloidosis patients with active treatment managed at a secondary hospital, was conducted during 2020. The study was carried out in two phases: first, the patient’s experience was analyzed through the IEXPAC questionnaire; second, an intervention was carried out to improve the worst-valued indicators. Results: The survey was conducted on 15 patients. The mean ± SD IEXPAC score was 3.8 ± 0.9. The best scores were those directed to the care offered by healthcare professionals. The worst scores were for obtaining information on Internet and use of the mobile phone to consult medical records. The application of the IEXPAC questionnaire resulted in the production of informative material. Conclusion: This is the first investigation that applies the IEXPAC questionnaire to patients with hATTR amyloidosis. This study supplies useful finding that may be used in future investigations to address hATTR amyloidosis patients’ needs and challenges on the way to patient-centered care.

  • Open Access

    Implementation of a novel home delivery service during pandemic

    by Ana Peláez Bejarano, Pilar Villar Santos, Maria de Las Aguas Robustillo-Cortés, Ernesto Sánchez Gómez, Maria Dolores Santos Rubio

    Introduction During the COVID-19 pandemic, measures have been put in place to adapt to patients’ needs during home quarantine, such as “telehealthcare”. With this service, hospital pharmacists develop a distinct role via the implementation of pharmacovigilance services and pharmaceutical care plans for patients with comorbidities, and for special populations as immunosuppressed patients. Methods Cross-sectional study involving hospital and community pharmacists actively practising during the COVID-19 pandemic. Patients who could not come to the hospital pharmacy department were provided with a delivery service to the community pharmacy of their choice. Results A total of 1186 patients requested this service. Erythropoiesis-stimulating agents were the most in-demand medication, followed by rheumatoid arthritis and antiretroviral drugs. 125 patients responded to the telephone survey, most of whom stated that they would use the delivery service again, and expressed their desire to continue doing so. Discussion Without a doubt, telepharmacy and medication delivery services have provided multiple benefits during home quarantine. The delivery service enabled us to provide drugs to patients in their immediate environment through a service that was free for both the patient and the hospital pharmacy service. However, at present, the available evidence of the impact of telepharmacy models is sparse. Conclusions This medication delivery service has provided multiple benefits to patients during home quarantine. Although the users of this service seem to be satisfied with the current model, in the future, we should consider which patients would benefit most from this service and shape it to individual needs.


  • Interstitial nephritis with pembrolizumab: A case report and review

    by A Peláez Bejarano, O Montero Pérez, A Inoriza Rueda, Mt Garrido Martínez

    Introduction: Pembrolizumab is a monoclonal antibody approved for adult patients with advanced non–small-cell lung cancer (NSCLC). Although immune related adverse events are considered to be well tolerated, complications may occur and discontinuation of the treatment could be required. Case report: A 62-year old patient diagnosed with advanced non-small cell lung cancer experienced a decline in the renal function after seven cycles with pembrolizumab. Management & outcome: After ruling out other common causes of interstitial nephritis, pembrolizumab was attributed as a cause of interstitial nephritis. At first, toxicity was managed with corticosteroids and closely monitoring the patient, but finally pembrolizumab had to be discontinued due to the kidney function did not recover. Discussion: Renal and urinary disorders were reported in <3% of patients treated with pembrolizumab, being interstitial nephritis the most reported toxicity. The kidney damage can be a complication to consider in patients receiving pembrolizumab. Early identification of an increase in serum creatinine levels may help with prevention by establishing an effective treatment, although it may not mean a total recovery of kidney function.


  • Bartonella henselaeencephalopathy in a paediatric patient: A case report and treatment review

    by Ana Peláez Bejarano, Raquel Sánchez del Moral, Ana Belen Guisado‐Gil

    What is known and objectives Bartonella henselae is the etiologic agent of “cat scratch disease (CSD)”. We describe a case of atypical CSD in a paediatric patient and include a review of the antibiotic treatment for this disease. Case description A 2‐year‐old child, with convulsive status and loss of consciousness, was admitted to hospital. Several antiepileptics and antibiotics were prescribed due to suspected central nervous system infection. When serology revealed Bartonella henselae antibodies, targeted antibiotic therapy was initiated and symptoms improved. However, seizures reappeared days after finishing the treatment so antiepileptics and antibiotics were reintroduced. What is new and conclusion A wide variety of antibiotic regimens have been used for the treatment of atypical CSD in paediatric patients. This report includes the case of a paediatric patient diagnosed with atypical CSD who presented neurological manifestations, and for which a regimen consisting of azithromycin and rifampin was employed to achieve recovery.